Pharmacotherapeutic advances for splenomegaly in myelofibrosis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2192350
Abstract: ABSTRACT Introduction Myelofibrosis is a hematologic malignancy with a variety of clinical manifestations including splenomegaly, which is present in approximately 80% of newly diagnosed patients. JAK inhibitors are the mainstay of pharmacologic treatment for splenomegaly… read more here.
Keywords: splenomegaly myelofibrosis; pharmacotherapeutic advances; advances splenomegaly; myelofibrosis ... See more keywords